Genetics of coagulation: Considerations for cardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 10, Issue 4, 2006, Pages 297-313

  Morozowich, Steven T ^a   Donahue, Brian S ^b   Welsby, Ian J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary bypass; Coagulation; Genes; Hemorrhage; Postoperative thrombosis; Thoracic surgery

Indexed keywords

BLOOD CLOTTING FACTOR;

AFIBRINOGENEMIA; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; DYSFIBRINOGENEMIA; GENE IDENTIFICATION; GENETIC VARIABILITY; HEART SURGERY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERHOMOCYSTEINEMIA; PERIOPERATIVE PERIOD; POPULATION RESEARCH; PREDICTION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; THROMBOSIS; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; CARDIAC SURGICAL PROCEDURES; HUMANS; PREOPERATIVE CARE; PROTEIN S DEFICIENCY; RISK FACTORS;

EID: 33750733292     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253206294345     Document Type: Review

References (152)

1. Fukutake K, Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan. Semin Thromb Hemost. 2000;26:29-32.
2. Smit C, Rosendaal FR, Varekamp I, et al. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. BMJ. 1989;298:235-238.
3. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;73:87-93.
4. Giannelli F, Green PM, Sommer SS, et al. Haemophilia B: database of point mutations and short additions and deletions - eighth edition. Nucleic Acids Res. 1998;26:265-268.
5. White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb.Haemost. 2001;85:560.
6. Escuriola Ettingshausen C, Halimeh S, Kurnik K, et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost. 2001;85:218-220.
7. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost. 2004;92:305-310.
8. MacKinlay N, Taper J, Renisson F, Rickard K. Cardiac surgery and catheterization in patients with haemophilia. Haemophilia. 2000;6:84-88.
9. Belaaouaj AA, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem. 2000;275:27123-27128.
10. Asakai, R., Chung DW, Ratnoff OD, Davie EW Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A. 1989;86:7667-7671.
11. Kessler, C. Hemorrhagic disorders: coagulation factor deficiencies. In: Goldman L, ed; Cecil Textbook of Medicine. 22nd ed. Philadelphia, PA: WB Saunders Company; 2004:1075-1076.
12. O'Connell NM. Factor XI deficiency - from molecular genetics to clinical management. Blood Coagul Fibrinolysis. 2003;14(suppl 1):S59-S64.
13. Bolton-Maggs PH. Factor XI deficiency and its management. Haemophilia. 2000;6(suppl 1):100-109.
14. Bolton-Maggs, P.H., Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost. 1995;73:194-202.
15. Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis. 2005;16:37-41.
16. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet. 1994;344:748-749.
17. Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood. 1994;84:1314-1319.
18. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol. 1997;96:293-297.
19. Martlew VJ. Peri-operative management of patients with coagulation disorders. Br J Anaesth. 2000;85:446-455.
20. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis. 1992;3:465-468.
21. Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia. 2002;8:145-148.
22. Nawabi IU, Garcia A, Mitter A, Brunner RE. Anticoagulation during CABG in factor XI deficiency, a case report. Thromb Haemost. 1994;71:261.
23. Brunken R, Follette D, Wittig J, Coronary artery bypass in hereditary factor XI deficiency. Ann Thorac Surg. 1984;38:406-408.
24. Ingram MD, Torpey DJ Jr. Management of factor XI deficiency in coronary artery bypass graft surgery by plasmapheresis and exchange transfusion. J Cardiothorac Anesth. 1989;3:203-206.
25. Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood. 1981;58:387-397.
26. Rodeghiero F, Castaman G, Dini E, Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-459.
27. Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol. 1984;57:163-169.
28. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71:520-525.
29. Schneppenheim R. The evolving classification of von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16(suppl 1):S3-S10.
30. van der Meer IM, Brouwers GJ, Bulk S, et al. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol. 2004;124:343-347.
31. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 2002;116:350-356.
32. Antoniades C, Tousoulis D, Vasiliadou C, et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol. 2005;46:1101-1109.
33. Gupta PK, Adamtziki E, Budde U, et al. Gene conversions are a common cause of von Willebrand disease. Br J Haematol. 2005;130:752-758.
34. Vincentelli A, Susen S, LeTourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343-349.
35. Yoshida K, Tobe S, Kawata M, Yamaguchi M. Acquired and reversible von Willebrand disease with high shear stress aortic valve stenosis. Ann Thorac Surg. 2006;81:490-494.
36. Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost. 2000;84:175-182.
37. Mannucci PM. Treatment of von Willebrand disease. Haemophilia. 1998;4:661-664.
38. Rick ME. Diagnosis and management of von Willebrand's syndrome. Med Clin North Am. 1994;78:609-623.
39. Halbmayer WM, Haushofer A, Schon R, et al. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemost. 1994;71:68-72.
40. Kelsey PR, Bottomley J, Grott GJ, Maciver JE. Congenital factor XII deficiency: successful open heart surgery and anticoagulation. Clin Lab Haematol. 1985;7:379-381.
41. Moorman RM, Reynolds DS, Comunale ME. Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J CardiothoracVasc Anesth. 1993;7:452-454.
42. Salmenpera M, Rasi V, Mattila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology. 1991;75:539-541.
43. Gerhardt MA, Greenberg CS, Slaughter TF, Stafford Smith M. Factor XII deficiency and cardiopulmonary bypass: use of a novel modification of the activated clotting time to monitor anticoagulation. Anesthesiology. 1997;87:990-992.
44. Gastmann O, Werner GS, Babic UU, Figulla HR. Thrombus formation on transcatheter ASD occluder device in a patient with coagulation factor XII deficiency. Cathet Cardiovasc Diagn. 1998;43:81-83.
45. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost. 1992;68:285-290.
46. Hasegawa T, Uematsu M, Tsukube T, Takemura Y, Okita Y. Huge left atrial thrombus with mitral stenosis in congenital factor XII deficiency. Ann Thorac Surg. 2002;73:286-288.
47. Lodi S, Isa L, Pollini E, Bravo AF, Scalvini A. Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction. Scand J Haematol. 1984;33:80-82.
48. Girolami A, Randi ML, Gavasso S, Lombardi AM, Spieza F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis. 2004;17:139-143.
49. Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. 1951;30:596-608.
50. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem. 1994;269:23357-23366.
51. Triplett DA, Brandt JT, Batard MA, Dixon JL, Fair DS. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood. 1985;66:1284-1287.
52. Giansily-Blaizot M, Biron-Andreani, Aguilar-Martinez P, et al. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol. 2002;117:172-175.
53. Mariani G, Herrmann FH, Schulman S, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1:2153-2158.
54. De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2002;123:951-958.
55. Elsner J, Kalweit G, Frehen D, Gams E. Substitution therapy of congenital factor VII deficiency at an extended operation with extracorporeal circulation. Eur J Cardiothorac Surg. 1999;16:387-388.
56. Ferster A, Capouet V, Deville A, Fondu P, Corazza F. Cardiac surgery with extracorporeal circulation in severe factor VII deficiency. Haemostasis. 1993;23:65-68.
57. Roberts HR, Escobar MA. Other clotting factor deficiencies. In: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silverstein LE, et al, eds. Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Churchill Livingstone, An Imprint of Elsevier; 2005:2081-2096.
58. Godje O, Haushofer M, Lamm P, Reichart B. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg. 1998;46:263-267.
59. Amini-Nekoo A, Futers TS, Moia M, Manucci PM, Grant RJ, Ariens RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol. 2001;113:537-543.
60. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. P1(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001;104:2666-2672.
61. Nielsen VG, Gurley WQ Jr, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg. 2004;99:120-123.
62. Hazirolan T, Perler BA, Bluemke DA. Floating thoracic aortic thrombus in "protein S" deficient patient. J Vasc Surg. 2004;40:381.
63. Ogasawara N, Kijima Y, Ike S, et al. Hereditary proteins deficiency with a history of recurrent myocardial infarction. Circ J. 2003;67:166-168.
64. Grocott HP, Clements F, Landolfo K. Coronary artery bypass graft surgery in a patient with hereditary protein S deficiency. J Cardiothorac Vasc Anesth. 1996;10:915-917.
65. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
66. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987;317:991-996.
67. Tireli E, Basaran M. Early Blalock-Taussig shunt thrombosis in a neonate with protein C deficiency. Ann Thorac Surg. 2004;77:2260-2261.
68. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995;73:876-889.
69. Oysel N, Bonnet J, Vergnes C, et al. Risk factors for myocardial infarction during coronary artery bypass graft surgery. Eur Heart J. 1989;10:806-815.
70. So GM, Herbert MR, Dooling EC, Buonanno F, Kosofsky BE, Ebb D. Multifocal embolie strokes following cardiac surgery in a protein C-deficient child. J Child Neurol. 1998;13:629-631.
71. Sievert A, McCall M, Blackwell M, Bradley S. Use of aprotinin during cardiopulmonary bypass in a patient with protein C deficiency. J Extra Corpor Technol. 2003;35:39-43.
72. Spanier TB, Chen JM, Mancini DM, Smith CR, Edwards NM. Cardiac transplantation in a patient with protein S deficiency. Ann Thorac Surg. 1999;68:1078-1080.
73. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest. 1984;74:2082-2088.
74. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64:1297-1300.
75. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
76. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-2761.
77. Villacorta J, Guidon C, Kerbaul F, Mesana T. An intraoperative coronary artery bypass graft thrombosis in a patient with protein S deficiency. [Erratum in: J Cardiothorac Vasc Anesth. 2002; 16:266.] J Cardiothorac Vasc Anesth. 2001;15:805-806.
78. De Paulis R, Bognolo G, Tomai F, Bassano C, Tracey M, Chiariello L. Early coronary artery bypass graft thrombosis in a patient with protein S deficiency. Eur J Cardiothorac Surg. 1996;10:470-472.
79. Lane DA, Bayston T, Olds RJ. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77:197-211.
80. Kuhle S, Lane DA, Jochmanns K, et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost. 2001;86:1007-1011.
81. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
82. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106-112.
83. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol. 1994;45:321-324.
84. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med. 2005;33:355-360.
85. Stump DA, Rogers AT, Hammon JW, Newman SP. Cerebral emboli and cognitive outcome after cardiac surgery. J Cardiothorac Vasc Anesth. 1996;10:113-118.
86. Cheung AT, Levin SK, Weiss SJ, Acker MA, Stenach N. Intracardiac thrombus: a risk of incomplete anticoagulation for cardiac operations. Ann Thorac Surg. 1994;58:541-542.
87. Loubser PG, McCarthy JJ, Attar M. Coronary thrombosis associated with antithrombin-III deficiency. J Cardiothorac Vasc Anesth. 1997;11:756-759.
88. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology. 1999;91:1122-1151.
89. Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion. 1998;38:481-498.
90. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005;130:107-113.
91. Konkle BA, Bauer KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003;43:390-394.
92. Brinks HJ, Weerwind PW, Verkroost MW, Novakova I, Brouwer MH. Familial antithrombin-III deficiency during cardiopulmonary bypass: a case report. Perfusion. 2000;15:553-556.
93. Matthai WH Jr, Kurnik PB, Groh WC, Untereker WJ, Siegel JE. Antithrombin activity during the period of percutaneous coronary revascularization: relation to heparin use, thrombotic complications and restenosis. J Am Coll Cardiol. 1999;33:1248-1256.
94. Sabbagh AH, Chung GK, Shittleworth P, Applegate BJ, Gabrhel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg. 1984;37:466-468.
95. Carrell N, Gabriel DA, Blatt PM, Carr ME, McDonagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood. 1983;62:439-447.
96. Welsby IJ, Podgoreanu MV, Phillips-Bute B, et al. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost. 2005;3:1206-1212.
97. Neerman-Arbez, M, The molecular basis of inherited afibrinogenaemia. Thromb Haemost. 2001;86:154-163.
98. al Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol. 1994;46:343-347.
99. Chun R, Poon MC, Haigh J, Seal D, Donahue B, Royston D. Case 1-2005: cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease. J Cardiothorac Vasc Anesth. 2005;19:109-117.
100. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet. 2002;11:2463-2468.
101. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945-959.
102. Jorde LB. Linkage disequilibrium and the search for complex disease genes. Genome Res. 2000;10:1435-1444.
103. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.
104. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
105. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
106. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
107. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol. 2000;65:45-49.
108. Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ. 1996;155:285-289.
109. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost. 1997;78:631-635.
110. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346: 1133-1134.
111. Donahue BS, Gailani D, Higgins MS, Drinkwater DC, George AL Jr. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation. 2003;107:1003-1008.
112. Sweeney JD, Blair AJ, Dupuis MP, King TC, Moulton AL. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion. 1997;37:1173-1178.
113. Donahue BS. Factor V Leiden and perioperative risk. Anesth Analg. 2004;98:1623-1634.
114. Moor E, Silveira A, van't Hooft F, et al. Coagulation factor V (Arg506→Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. Thromb Haemost. 1998;80:220-224.
115. Sampram ES, Lindblad B. The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions. Eur J Vasc Endovasc Surg. 2001;22:134-138.
116. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
117. Pollak ES, Lam HS, Russell JE. The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood. 2002;100:359-362.
118. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
119. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531-3544.
120. Hathcock J. Vascular biology-the role of tissue factor. Semin Hematol. 2004;41(1 suppl 1):30-34.
121. Kokawa T, Enjyoji K, Kumeda K, et al. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol. 1996;16:802-808.
122. Adams MJ, Cardigan RA, Marchant WA, et al. Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2002;16:59-63.
123. Sun LB, Utoh J, Kunitomo R, et al. Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery. Surg Today. 2000;30:122-126.
124. Holst J, Lindblad B, Bergqvist D, Hedner U, Nordfang O, Ostergaard P. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Thromb Res. 1997;86:343-348.
125. Salemink I, Frannsen J, Willems GM, et al. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost. 1998;80:273-280.
126. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002;30:1729-1734.
127. Li A, Wun TC. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost. 1998;80:423-427.
128. Bombeli T, Piccapieti B, Boersma J, Fehr J. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia. Thromb Haemost. 2004;91:80-86.
129. Ameziane N, Seguin C, Borgel D, et al. The -33T→C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb Haemost. 2002;88:195-199.
130. Moatti D, Haidar B, Fumeron F, et al. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost. 2000;84:244-249.
131. Moatti D, Meirhaeghe A, Ollivier V, Bauters C, Amouyel P, de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis. 2001;12:317-323.
132. Moatti D, Seknadji P, Galand C, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol. 1999;19:862-869.
133. Kleesiek K, Schmidt M, Gotting C, et al. The 536C→ T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost. 1999;82:1-5.
134. Guimaraes AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol. 2004;124:659-665.
135. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053-2058.
136. Morange PE, Tregouet DA, Frere C, et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost. 2005;3:1503-1510.
137. Akatsu H, Yamagata H, Chen Y, et al. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. Br J Haematol. 2004;127:440-447.
138. Kostka, H, Kuhlisch E, Schellong S, Siegert G. Polymorphisms in the TAFI gene and the risk of venous thrombosis. Clin Lab. 2003;49:645-647.
139. Lichy C, Dong-Si T, Reuner K, et al. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems. J Neurol. 2006;253:316-320.
140. Zorio E, Castello R, Falco C, et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol. 2003;122:958-965.
141. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
142. Poston R, Gu J, Manchio J, et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg. 2005;27:584591.
143. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73:122-130.
144. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003;42:1115-1119.
145. Morawski W, Sanak M, Cisowski M, et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg. 2005;130:791-796.
146. Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol. 2005;95:805-808.
147. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000;101:1013-1018.
148. Honda S, Honda Y, Bauer B, Ruan C, Kunicki TJ. The impact of three-dimensional structure on the expression of PlA alloantigens on human integrin beta 3. Blood. 1995;86:234-242.
149. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004;15:89-93.
150. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001;98:3256-3260.
151. Golanski J, Golanski R, Chizynski K, et al. Platelet hyperreactivity after coronary artery bypass grafting: the possible relevance to glycoprotein polymorphisms. A preliminary report. Platelets. 2001;12:241-247.
152. Potapov EV, Ignatenko S, Nasseri BA, et al. Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support. Ann Thorac Surg. 2004;77:869-874.